Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3 Gynecologic 2 Gastrointestinal 2 Breast 2 Thoracic 1 Other solid neoplasm 1 Other 1 Lymphoid 1 Head & Neck 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 65 Nivolumab 58 Ipilimumab 32 Cyclophosphamide 22 Specimen Handling 16 Magnetic Resonance Spectroscopy 15 Biopsy 15 relatlimab 13 cemiplimab 13 fludarabine 12 Opdualag 12 binimetinib 10 Blood Specimen Collection 10 aldesleukin 9 Radiosurgery 9 encorafenib 8 Interleukin-2 8 atezolizumab 7 Immunotherapy 7 tebentafusp 6 mogamulizumab 6 fludarabine phosphate 6 Temozolomide 6 Surgical Procedures, Operative 6 Paclitaxel 6 Immunoglobulin G 6 CTLA-4 Antigen 6 Radiotherapy 5 Disulfides 5 Bevacizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Hydroxychloroquine × Dermatologic × Clear all

NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡